Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02604849
Other study ID # FCO-NEE-2015-01
Secondary ID
Status Completed
Phase N/A
First received November 10, 2015
Last updated November 12, 2015
Start date July 2012
Est. completion date November 2015

Study information

Verified date November 2015
Source Maimónides Biomedical Research Institute of Córdoba
Contact n/a
Is FDA regulated No
Health authority Spain: Agencia Española de Medicamentos y Productos Sanitarios
Study type Observational

Clinical Trial Summary

The identification of all cases (44 patients) was carried out from the database of microbiology, University Hospital Reina Sofía and the University Hospital of Jerez. For the identification of controls, in case of neutropenic patients, all colonized patients that were included during the study period did not receive any decolonitation treatment; in case of non-neutropenic patients it was studied a paired control by the presence of risk factors that indicated the beginning of decolonitation treatment.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date November 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with intestinal colonization by Klebsiella pneumoniae, defined as the presence of a positive rectal swab culture at least 7 days prior to initiation of therapy; and patients considered at risk of developing an invasive infection by Klebsiella pneumoniae:

- Surgery in two weeks

- Transplant in two weeks

- Require medical intervention or has a clinical situation that may predispose to the development of a serious infection (chemotherapy, immunosuppression or neutropenia)

- Recurrent or severe infections

- Institution admission

- Fragile patients at high risk of readmission.

Exclusion Criteria:

- The presence of an active infection for Klebsiella Pneumoniae.

- Concomitant use of systemic antibiotics in the 14 days before the start of decolonization therapy.

Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Drug:
Neomycin

Streptomycin

Gentamicins


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Maimónides Biomedical Research Institute of Córdoba

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality for any cause during a six-months period after oral therapy gut decontamination. 6 months